At the beginning of the systemic therapy after tumor progression during ET plus CDK4/6i treatment, patient age, the number of metastatic sites, the presence of visceral involvement, and the type of treatment (ET vs CT based) were similarly distributed in BRCA1/2 mutated vs wild-type groups. This evidence concerns the gene BRCA1 and neoplasm.